Binex Co

Binex Co EBIT Margin

The EBIT Margin (Operating Margin) of Binex Co (053030.KQ) as of Oct 27, 2026 is -1.14 %. In the previous year, EBIT Margin (Operating Margin) was -28.59 % — a change of -96.00% (higher).

EBIT Margin

-1.14 %

YoY

-96.00%

Last updated:

EBIT Margin (Operating Margin) of Binex Co is 2025 -1.14 % . EBIT Margin (Operating Margin) of Binex Co was 2024 -28.59 % . It decreases by -96.00% higher compared to the previous year.

Binex Co's operating (EBIT) margin stands at -1.1%, down from 9.4% several years earlier.

The Binex Co EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
6.61 KRW
Jan 1, 2019
9.00 KRW
Jan 1, 2020
5.49 KRW
Jan 1, 2021
9.38 KRW
Jan 1, 2022
10.96 KRW
Jan 1, 2023
2.17 KRW
Jan 1, 2024
-28.59 KRW
Jan 1, 2025
-1.14 KRW
The Binex Co EBIT Margin history
YEAREBIT MarginYoY
-1.14 %-96.00%
-28.59 %-1,415.28%
2.17 %-80.17%
10.96 %+16.84%
9.38 %+70.85%
5.49 %-38.99%
9.00 %+36.15%
6.61 %-159.31%
-11.15 %+225.91%
-3.42 %+69.83%
-2.01 %-165.60%
3.07 %-2,916.83%
-0.11 %-3,161.92%
0.00-94.73%
0.07 %-275.51%
-0.04 %-388.12%
0.01 %-87.78%
0.11 %+10.10%
0.10 %-16.20%
0.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Binex Co Stock analysis

What does Binex Co do? Binex Co Ltd generates revenue through the manufacturing and sale of pharmaceutical products including digestive system agents, circulatory system agents, ulcer agents, antacids, anti-inflammatory agents, analgesics, gastrointestinal tract regulators, antispasmodics, antiemetic drugs, antihistamines, laxatives, antihypertensive and urinary agents, antibacterial and antibiotic agents, cough and cold remedies, anti-diabetic medicines, ophthalmic solutions, vitamins, nutrients, and various ointments and creams. The company also produces bio medicines and raw materials. Binex Co Ltd distributes its products domestically within Busan and to overseas markets, targeting healthcare providers, pharmacies, and hospitals that purchase pharmaceuticals for patient care and treatment. The firm's product portfolio covers a wide range of therapeutic areas, including gastrointestinal health, cardiovascular support, pain management, respiratory care, and chronic disease management. By offering both branded and generic pharmaceutical solutions, Binex Co Ltd serves diverse customer segments across the domestic and international pharmaceutical markets, leveraging its manufacturing capabilities to meet regional healthcare demands. Binex Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Binex Co stock

EBIT Margin (Operating Margin) of Binex Co is -1.14 % in 2025.

EBIT Margin (Operating Margin) of Binex Co changed from -28.59 % to -1.14 %, representing a -96.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Binex Co since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Binex Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Binex Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Binex Co